Correlation Engine 2.0
Clear Search sequence regions

  • control group (1)
  • donors (3)
  • leukemia (8)
  • patients (13)
  • region (1)
  • rna (7)
  • SHP 1 (12)
  • SOCS6 (10)
  • Src (1)
  • Sizes of these terms reflect their relevance to your search.

    To investigate the expression and clinical relevance of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and suppressor of cytokine signaling 6 (SOCS6) in acute leukemia (AL). The enrolled AL patients were divided into three groups (newly diagnosed, relapsed, and complete remission [CR]). Healthy donors were also included as a control group in this study. Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed to measure messenger RNA (mRNA) expression of SHP-1 and SOCS6. Statistical analysis was conducted to analyze the correlation between mRNA levels of SHP-1 and SOCS6 with patient outcomes. mRNA expression of SHP-1 was significantly lower in AL patients than that in healthy donors. The newly diagnosed or relapsed AL patients had lower mRNA levels of SHP-1 than the patients in CR. In contrast, SOCS6 mRNA expression was significantly higher in newly diagnosed or relapsed patients than that in patients in CR as well as healthy donors. However, mRNA levels of both SHP-1 and SOCS6 were positively correlated with the patient remission. The chemotherapy-induced remission rate was higher in patients with detectable SHP-1 or SOCS6 expression than in patients with undetectable SHP-1 or SOCS6 expression. Furthermore, the AL patients with detectable SHP-1 mRNA expression had lower incidence rate of invasive fungal infection. The results suggest that expression patterns of SHP-1 and SOCS6 differ in AL patients. Despite the difference, expression of SHP-1 and SOCS6 is associated with favorable outcomes, suggesting an anticancer property of these two genes in AL.


    Jinmei Liu, Yurong Zheng, Ju Gao, Guimei Zhu, Kun Gao, Wenzhen Zhang, Fangyan Shi, Qing Zhang. Expression of SHP-1 and SOCS6 in patients with acute leukemia and their clinical implication. OncoTargets and therapy. 2017;10:1915-1920

    PMID: 28408843

    View Full Text